Flotek Industries announced its third quarter 2026 revenue reached $114.4 million, the highest in 12 years, doubling from the previous year due to strong growth in its Data Analytics and Chemistry Technologies segments. Despite a 35% drop in net income compared to Q3 2025, the company increased its full-year 2026 revenue guidance to $382-$390 million and adjusted EBITDA guidance to $59-$62 million. Flotek plans significant capital investments in 2027 to expand its Data Analytics segment, supported by a recently closed term loan. This growth reflects Flotek's strategic pivot towards data-driven technology solutions beyond the oil and gas industry.
Flotek's quarterly revenue milestone provides context for energy sector performance on Pluang. For readers following the energy sector, here is Pluang's market snapshot as of Nov 04, 2026 04:21 WIB: Among 79 priced US energy stocks, 27 rose and 51 fell. Notable movers include EQNR at USD 45.42 with a 1-day change of -6.83% and 100% buy order activity, CVE at USD 30.68 down 6.29%, and RUN at USD 8.75 up 6.06% with a typical hold time of 17 days.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
